소세포폐암 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• As per DelveInsight, the Small Cell Lung Cancer Market is expected to expand at a healthy growth rate during the forecast period (2026-2036), owing to the launch of new therapies in the market and the rise in the number of cases.
• Key Small Cell Lung Cancer companies such as Ipsen Biopharmaceuticals (Onivyde), Bristol-Myers Squibb (BMS-986012), Xcovery Holding Company (Vorolanib), EpicentRx (RRx-001), Amgen (AMG 757), and others are evaluating their lead candidates in different stages of clinical development, respectively.
• Lung cancer affects more than 200,000 people in the United States each year and an estimated 2.3 million people worldwide each year. About 10% to 15% of people with lung cancer have a type called Small Cell Lung Cancer.
• The 5-year relative survival rate for people with Small Cell Lung Cancer in the United States is 8% for women and 6% for men.
• Certain treatments available for Small Cell Lung Cancer encompass the usage of IMFINZI (durvalumab) to address extensive-stage- Small Cell Lung Cancer, and ZEPZELCA (lurbinectedin) for the treatment of patients with metastatic Small Cell Lung Cancer.
• About 25% of individuals with limited-stage Small Cell Lung Cancer can be cured with prompt treatment with chemotherapy and radiation therapy.
• The preferred treatment approach, which has been in use for several decades, involves the administration of platinum etoposide. In the conventional approach, topotecan is used as a second-line treatment, particularly for patients who respond well to platinum-based therapy. While topotecan exhibits a response rate of approximately 20%, its impact on improving survival is comparatively modest when compared to the best supportive care available.
• The number and clinical effectiveness of treatment options for Small Cell Lung Cancer lag far behind that of non-Small Cell Lung Cancer, which has seen an explosion of targetable pathways and better responses to immunotherapy.
• In recent times, immunotherapy has emerged as the most promising treatment modality for individuals diagnosed with Small Cell Lung Cancer. Nonetheless, several challenges persist in utilizing these agents effectively, including concerns related to both their toxicity and efficacy. To adequately address the diverse subtypes of this disease, there is a pressing need for additional treatment options.

DelveInsight's "Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of the Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Small Cell Lung Cancer market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. Small Cell Lung Cancer market report provides current treatment practices, emerging drugs, market share of individual therapies, and historical and forecasted Small Cell Lung Cancer market size from 2022 to 2036. The report also covers current Small Cell Lung Cancer treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2022-2036

Small Cell Lung Cancer Treatment Market

Small Cell Lung Cancer Overview

Small Cell Lung Cancer is an aggressive form of lung cancer. It is characterized by rapid, uncontrolled growth of certain cells in the lungs. Eventually, a tumor forms and the cancer can spread (metastasize) to other areas of the body. The primary risk factor is tobacco use; almost all affected individuals smoke or have a history of smoking. Symptoms can vary from one person to another, and there are rarely any symptoms early in the course of the disease.

Small Cell Lung Cancer Diagnosis

If lung cancer is suspected, the physician will recommend imaging tests (CT, PET, or MRI scans) to identify abnormalities in and around the lungs. Physicians may also take a sample of the mucus to look for cancer cells. If these initial tests identify cancer, a biopsy can be performed by either inserting a needle or making an incision in the chest to remove a small bit of tissue from your lung for further inspection. Another technique physicians commonly use to both visualize and remove lung tissue is called bronchoscopy.

The physician will also determine the extent to which the Small Cell Lung Cancer has spread throughout your body. This descriptive process, called staging, can help inform treatment. Although numerical stages are used for Small Cell Lung Cancer as well as for other cancers, Small Cell Lung Cancer is often classified as either limited-stage disease (LD), where the cancer is confined to a reasonable radiation field within the chest, or extensive-stage disease (ED), where cancer has spread outside the chest.

Small Cell Lung Cancer is rarely detected early. However, with appropriate CT screening for certain patients with a history of smoking, it is occasionally diagnosed before it causes symptoms. Early diagnosis offers the best prognosis for Small Cell Lung Cancer.

Small Cell Lung Cancer Treatment

Small Cell Lung Cancer Treatment options and recommendations depend on several factors, including the type and stage of cancer, possible side effects, and the patient's preferences and overall health. The most common treatments for Small Cell Lung Cancer are:

• surgery
• radiotherapy
• chemotherapy
• chemotherapy with radiotherapy (chemoradiotherapy)
• immunotherapy
• targeted cancer drugs

Small Cell Lung Cancer Epidemiology

The Small Cell Lung Cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented total incident cases of Small Cell Lung Cancer, gender-specific incident cases of Small Cell Lung Cancer, age-specific incident cases of Small Cell Lung Cancer, line-wise treated cases of Small Cell Lung Cancer in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2022 to 2036.

• In the US, SCLC accounted for about 37,000 cases in 2025.
• About 80% of SCLC cases were in population aged 65 or older, reflecting the advanced median age of diagnosis 71 years.
• In 2025, ~20% of SCLC cases upstaged from limited to extensive stage in 7MM.
• In 2025, males accounted for approximately 55% of total SCLC cases in the US.

Get a more detailed overview of How Small Cell Lung Cancer Epidemiology will evolve in the upcoming years: Small Cell Lung Cancer Epidemiology Forecast

Recent Developments Small Cell Lung Cancer Clinical Trials

• In March 2026, EMA recommended granting a marketing authorisation in the European Union (EU) for tarlatamab (IMDYLLTRA) as monotherapy to treat adults with ES-SCLC whose disease relapsed during or after an initial treatment with platinum-based chemotherapy.
• In December 2025, GSK5764227 received Orphan Drug Designation (ODD) from US FDA for the treatment of SCLC.
• In October 2025, GSK announced that GSK5764227 received ODD from the EMA for the treatment of pulmonary neuroendocrine carcinoma (NEC), a category of cancer that includes SCLC. The ODD was supported by preliminary clinical data showing durable responses in patients with extensive stage SCLC (ES-SCLC) who were treated with GSK5764227 in the Phase I (ARTEMIS-001) clinical trial.

Small Cell Lung Cancer Drug Chapters

The drug chapter segment of the Small Cell Lung Cancer market report encloses a detailed analysis of Small Cell Lung Cancer marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the Small Cell Lung Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and recent deals and collaborations.

Marketed Small Cell Lung Cancer Drugs

ZEPZELCA (lurbinectedin): PharmaMar and Jazz Pharmaceuticals

In June 2020, the US Food and Drug Administration granted accelerated approval to ZEPZELCA (lurbinectedin) for adult patients with metastatic Small Cell Lung Cancer with disease progression on or after platinum-based chemotherapy. ZEPZELCA, also known as PM1183, is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of the cell cycle and eventual cell death. ZEPZELCA is the first new drug approved for second-line treatment since 1996. ZEPZELCA offers several benefits over the standard therapy, HYMCAMTIN, with one notable advantage being a shorter treatment window. When administering ZEPZELCA intravenously, the process lasts for a mere hour, occurring once every three weeks. Conversely, the older therapy necessitates a more time-consuming regimen, requiring a five-day intravenous course of treatment every three weeks.

IMFINZI (durvalumab): AstraZeneca

In March 2020, the US Food and Drug Administration approved IMFINZI (durvalumab), in combination with etoposide and either carboplatin or cisplatin as the first-line treatment of patients with extensive-stage Small Cell Lung Cancer. IMFINZI is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumor's immune-evading tactics and releasing the inhibition of immune responses.

Emerging Small Cell Lung Cancer Drugs

Risvutatug rezetecan (GSK5764227): GSK

GSK5764227 is a novel investigational B7-H3-targeted antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights (excluding China's mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of GSK5764227. GSK's global Phase III trial for GSK5764227 in relapsed ES-SCLC began in August 2025. GSK5764227 was granted Priority Medicines (PRIME) Designation by the EMA for relapsed or refractory ES-SCLC and Breakthrough Therapy Designation (BTD) for relapsed or refractory ES-SCLC by the US FDA.

In October 2025, GSK announced that GSK5764227 received ODD from the EMA for the treatment of pulmonary neuroendocrine carcinoma (NEC), a category of cancer that includes SCLC. The ODD was supported by preliminary clinical data showing durable responses in patients with extensive stage SCLC (ES-SCLC) who were treated with GSK5764227 in the Phase I (ARTEMIS-001) clinical trial.

Sacituzumab govitecan (TRODELVY): Gilead Sciences

Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugate. Sacituzumab govitecan is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the tumor microenvironment through a bystander effect. It is currently in Phase III clinical development.

In December 2024, Sacituzumab govitecan received BTD from US FDA for the treatment of adult patients with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy.

ABBV-706: AbbVie

ABBV-706 is a seizure protein 6 homolog (SEZ6) targeted antibody-drug conjugate with a topoisomerase 1 inhibitor (Top1i) payload being investigated for the treatment of certain solid tumors. It is currently in Phase II clinical development. In October 2025, AbbVie announced presentation of new ABBV-706 data at ESMO 2025.

Explore more about the emerging therapies and key companies actively working in the market: Small Cell Lung Cancer Pipeline Insights

Small Cell Lung Cancer Drug Class Insights

Immunotherapies, including immune checkpoint inhibitors (ICIs), have revolutionized the treatment of various cancers and have emerged as a topic of immense interest in the case of Small Cell Lung Cancer (Small Cell Lung Cancer). Notably, recent advancements have shown improved survival rates in extensive-stage Small Cell Lung Cancer through the incorporation of anti-programmed death ligand 1 (PD-L1) inhibitors alongside platinum-based chemotherapy as the primary treatment. Consequently, the combination of chemoimmunotherapy has now gained official approval as the standard of care.

Researchers are actively exploring the potential applications of ICIs in alternative scenarios as well. For instance, investigations are underway to evaluate the effectiveness of ICIs as consolidation therapy in limited-stage Small Cell Lung Cancer following chemoradiation, as well as in combination with chemoradiation. It is worth noting that the benefits of ICIs in Small Cell Lung Cancer cannot be reliably determined based solely on PD-L1 expression and tumor mutational burden. Consequently, there is an ongoing pursuit for predictive biomarkers that can accurately determine the response to ICIs in Small Cell Lung Cancer.

Innovative immunotherapeutic approaches are currently being investigated in the context of Small Cell Lung Cancer. These approaches are founded upon a comprehensive understanding of Small Cell Lung Cancer biology and the immune tumor microenvironment. Some promising strategies include combinations with inhibitors targeting TIGIT or LAG3, targeting alternative signaling pathways like DNA damage repair, and co-targeting Small Cell Lung Cancer-specific tumor antigens such as fucosyl-GM1 and DLL3. Each subtype of Small Cell Lung Cancer demonstrates unique vulnerability to different therapies, including PARP inhibitors, Aurora kinases, BCL-2, and more.

Small Cell Lung Cancer Market Outlook

For the last three decades, there has been minimal progress in enhancing the survival rates of patients afflicted with Small Cell Lung Cancer. Unfortunately, the clinical outcomes for these patients continue to be unfavorable primarily due to the disease's rapid cell division, propensity for early and extensive metastasis, and the development of resistance to chemotherapy.

There are a number of treatment options for Small Cell Lung Cancer. These treatment options are used to treat a specific patient's lung cancer that depends on the stage of cancer, the patient's overall health, including how well the organs of the patient's body are functioning, and the patient's preferences. Surgery, chemotherapy, radiation therapy, and immunotherapy are approved and mainly used treatment choices. The choice of treatment option is dependent on the stage of Small Cell Lung Cancer, symptoms, age, how fast it is growing, and whether patients may suffer various patterns of recurrence requiring subsequent lines of rescue therapies. The most commonly used chemotherapy regimen is Etoposide or Irinotecan plus a platinum-based drug such as Cisplatin or Carboplatin. For people with limited-stage Small Cell Lung Cancer, chemotherapy plus radiation therapy to the chest is given daily over several weeks. People with extensive-stage cancer initially receive chemotherapy for 3 to 4 months or they may receive chemotherapy in combination with immunotherapy.

Initially, the approval of anti-PD-1 agents such as nivolumab (OPDIVO) and pembrolizumab (KEYTRUDA) took place, gradually followed by the approval of atezolizumab (TECENTRIQ) in 2019, and subsequently, durvalumab in 2020, all in the first-line treatment setting. Furthermore, lubenetidin received approval for use in the second-line setting, while trilaciclib was approved for use in the first-line setting to mitigate chemotherapy-induced myelosuppression. However, in 2021, the approval of nivolumab and pembrolizumab in the subsequent-line setting was withdrawn. Nevertheless, they are still utilized in combination with chemotherapy and immune therapies such as atezolizumab and durvalumab in the first-line setting.

Currently, investigators are evaluating novel agents that have the potential to reshape the treatment landscape for extensive-stage Small Cell Lung Cancer, similar to the advancements witnessed in non-Small Cell Lung Cancer. Immune checkpoint inhibitors and the advancement of immunotherapy offer a fresh therapeutic approach for patients with Small Cell Lung Cancer. As the understanding of biomarkers in Small Cell Lung Cancer continues to expand within the field of oncology, the outcomes for patients with Small Cell Lung Cancer may eventually align more closely with those observed in the non-Small Cell Lung Cancer population.

Key Small Cell Lung Cancer companies such as Ipsen Biopharmaceuticals (Onivyde), Bristol-Myers Squibb (BMS-986012), Xcovery Holding Company (Vorolanib), EpicentRx (RRx-001), Amgen (AMG 757), and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Small Cell Lung Cancer.

Small Cell Lung Cancer Drugs Uptake

This section focuses on the uptake rate of potential Small Cell Lung Cancer drugs expected to be launched in the Small Cell Lung Cancer market during 2020-2034. For example, the bispecific T-cell engager tarlatamab (AMG 757) combining the binding specificities of DLL3 and CD3 is currently in a Phase II pivotal DeLLphi-301 study in Small Cell Lung Cancer. Based on the safety and efficacy data, existing and emerging competitors along with order of entry of this product, it is expected to undergo a specific type of uptake, which could vary from slow, medium and fast uptake in a specific number of years to attain its peak.

Small Cell Lung Cancer Pipeline Development Activities

The Small Cell Lung Cancer therapeutics market report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes the Small Cell Lung Cancer companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Small Cell Lung Cancer drug market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Small Cell Lung Cancer emerging therapies.

KOL Views

To remain in line with the evolving Small Cell Lung Cancer market trends, we take Industry experts opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on SCLC evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, include Medical/scientific writers, Medical Oncologists, Pulmonologists and Professors, Chief of Thoracic Service at the Memorial Sloan Kettering Cancer Center, and Others.

Delveinsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, Texas, UT Southwestern Medical Center in Dallas, Cancer Research UK Barts Centre in London, LUNGevity Foundation, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns, acceptability and accessibility issues along with Small Cell Lung Cancer market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging Small Cell Lung Cancer therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Small Cell Lung Cancer Market Access and Reimbursement

Lurbinectedin is cost-effective when compared with other second-line options for Small Cell Lung Cancer. Even though the acquisition cost of lurbinectedin is greater, this is offset by the lower cost of managing myelosuppression, when compared with other commonly used second-line therapies. Lurbinectedin is not only safe and effective but is also cost-effective in the care of patients with relapsed Small Cell Lung Cancer.

The Small Cell Lung Cancer market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Small Cell Lung Cancer Market Report

• The Small Cell Lung Cancer market report covers a segment of key events, an executive summary, descriptive overview of Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression along with treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of theSmall Cell Lung Cancer market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Small Cell Lung Cancer treatment market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Small Cell Lung Cancer market.

Small-cell Lung Cancer Market Report Insights

• Small Cell Lung Cancer Patient Population
• Small Cell Lung Cancer Therapeutic Approaches
• Small cell Lung Cancer Pipeline Analysis
• Small cell Lung Cancer Market Size
• Small Cell Lung Cancer Market Trends
• Existing and future Small Cell Lung Cancer Market Opportunity

Small-cell Lung Cancer Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Small-cell Lung Cancer Epidemiology Segmentation
• Key Cross Competition
• Small Cell Lung Cancer Conjoint analysis
• Small Cell Lung Cancer Drugs Uptake
• Key Small Cell Lung Cancer Market Forecast Assumptions

Small Cell Lung Cancer Market Report Assessment

• Current Small Cell Lung Cancer Treatment Practices
• Unmet Needs
• Small Cell Lung Cancer Pipeline Product Profiles
• Small Cell Lung Cancer Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

• What was the Small Cell Lung Cancer market size, the market size by therapies, and market share (%) distribution in 2022, and what would it look like in 2036? What are the contributing factors for this growth?
• How will DLL3 Targeted T-Cell Engager as a new class affect the treatment paradigm inSmall Cell Lung Cancer?
• What kind of uptake will PD-L1 inhibitors witness in the coming 11 years?
• Why in the case of platinum-refractory (PR) patients, usage of platinum-based therapy can be seen especially in the case of Japan?
• What will be the impact of Lurbinectedin's formulation patent expiry in 2028?
• Which class is going to be the largest contributor in 2036?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the Small Cell Lung Cancer market dynamics and subsequent analysis of the associated trends?
• What are the disease risk, burdens, and unmet needs of Small Cell Lung Cancer? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Small Cell Lung Cancer?
• What is the historical and forecasted Small Cell Lung Cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What are the current options for the treatment of Small Cell Lung Cancer? What are the current treatment guidelines for the treatment of Small Cell Lung Cancer in the US and Europe?
• How many emerging SCLC therapies are in the mid-stage and late stage of development for the treatment of Small Cell Lung Cancer?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing SCLC therapies?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focusing on reimbursement policies.

Reasons to buy:

• The SCLC Market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving theSmall Cell Lung Cancer Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Small Cell Lung Cancer market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming Small Cell Lung Cancer companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing Small Cell Lung Cancer therapeutics market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Small-cell Lung Cancer Market Overview at a Glance

• 6.1. Total Market Share (%) Distribution by therapies in 2022
• 6.2. Total Market Share (%) Distribution by therapies in 2036

7. Small Cell Lung cancer (SCLC): Disease Background and Overview

• 7.1. Introduction
  • 7.1.1. Signs and Symptoms of Lung Cancer
  • 7.1.2. Risk Factors of Small-cell Lung Cancer
  • 7.1.3. Causes of Small-cell Lung Cancer
  • 7.1.4. Disease Biology: Small-cell Lung Cancer
• 7.2. Diagnosis of Small-cell Lung Cancer (Small-cell Lung Cancer)
  • 7.2.1. Imaging tests
  • 7.2.2. Staging in Small-cell Lung Cancer

8. Small Cell Lung Cancer Epidemiology and Patient Population: 7MM

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: 7MM
• 8.3. Total Incident of Lung Cancer in the 7MM
• 8.4. Total Incident cases of Small-cell Lung Cancer in the 7MM
• 8.5. The United States
  • 8.5.1. Total Incident cases of Small-cell Lung Cancer in the United States
  • 8.5.2. Gender-specific Incident of Small-cell Lung Cancer in the United States
  • 8.5.3. Age-specific Incident of Small-cell Lung Cancer in the United States
  • 8.5.4. Stage-Specific Incident of Small-cell Lung Cancer in the United States
  • 8.5.5. Line-wise Treatment of Small-cell Lung Cancer in the United States
• 8.6. EU4 and the UK
  • 8.6.1. Total Incident cases of Small-cell Lung Cancer in EU4 and the UK
  • 8.6.2. Gender-specific Incident of Small-cell Lung Cancer in EU4 and the UK
  • 8.6.3. Age-specific Incident of Small-cell Lung Cancer in EU4 and the UK
  • 8.6.4. Stage-Specific Incident of Small-cell Lung Cancer in EU4 and the UK
  • 8.6.5. Line-wise Treatment of Small-cell Lung Cancer in EU4 and the UK
• 8.7. Japan
  • 8.7.1. Total Incident cases of Small-cell Lung Cancer in Japan
  • 8.7.2. Gender-specific Incident of Small-cell Lung Cancer in Japan
  • 8.7.3. Age-specific Incident of Small-cell Lung Cancer in Japan
  • 8.7.4. Stage-Specific Incident of Small-cell Lung Cancer in Japan
  • 8.7.5. Line-wise Treatment of Extensive-Stage Small-cell Lung Cancer in Japan

9. Current Treatment Practices for Small-cell Lung Cancer (Small-cell Lung Cancer)

• 9.1. Management Algorithm of Small-cell Lung Cancer
• 9.2. Small-cell Lung Cancer Treatment Paradigm
• 9.3. Radiation Therapy
• 9.4. Surgery
• 9.5. Metastatic Lung Cancer
• 9.6. Remission and the Chance of Recurrence
• 9.7. Guidelines for Small-cell Lung Cancer
  • 9.7.1. Treatment Differences across in the 7MM
  • 9.7.2. ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
  • 9.7.3. The American College of Chest Physicians (ACCP) Clinical Practice Guidelines: Small-cell Lung Cancer

10. Small Cell Lung Cancer Patient Journey

11. Key Endpoints in Small-cell Lung Cancer Clinical Trials

12. Marketed Small Cell Lung Cancer Products

• 12.1. Key Competitors
• 12.2. TECENTRIQ: Hoffmann-La Roche
  • 12.2.1. Product Description
  • 12.2.2. Regulatory Milestones
  • 12.2.3. Other Developmental Activities
  • 12.2.4. Pivotal Clinical Trials
  • 12.2.5. Ongoing Clinical Trials Information
  • 12.2.6. Safety and Efficacy of Ongoing Trials
• 12.3. IMFINZI: AstraZeneca
  • 12.3.1. Product Description
  • 12.3.2. Regulatory Milestones
  • 12.3.3. Other Developmental Activities
  • 12.3.4. Pivotal Clinical Trials
  • 12.3.5. Ongoing Clinical Trials Information
  • 12.3.6. Safety and Efficacy of Ongoing Trials
• 12.4. ZEPZELCA: Pharma Mar/Jazz
  • 12.4.1. Product Description
  • 12.4.2. Regulatory Milestones
  • 12.4.3. Other Developmental Activities
  • 12.4.4. Pivotal Clinical Trials
  • 12.4.5. Ongoing Clinical Trials Information
  • 12.4.6. Safety and Efficacy of Ongoing Clinical Trials

13. Emerging Small Cell Lung Cancer Therapies

• 13.1. Key Cross
• 13.2. ONIVYDE: Ipsen Biopharmaceuticals
  • 13.2.1. Product Description
  • 13.2.2. Regulatory Milestones
  • 13.2.3. Other Developmental Activities
  • 13.2.4. Clinical Development
  • 13.2.5. Safety and Efficacy
• 13.3. BMS-986012: Bristol-Myers Squibb
  • 13.3.1. Product Description
  • 13.3.2. Other Developmental Activities
  • 13.3.3. Clinical Development
  • 13.3.4. Safety and Efficacy
• 13.4. RRx-001: EpicentRx
  • 13.4.1. Product Description
  • 13.4.2. Other Developmental Activities
  • 13.4.3. Clinical Development
  • 13.4.4. Safety and Efficacy
• 13.5. Vorolanib: Xcovery Holding Company
  • 13.5.1. Product Description
  • 13.5.2. Other Developmental Activities
  • 13.5.3. Clinical Development
  • 13.5.4. Safety and Efficacy
• 13.6. Tarlatamab (AMG 757): Amgen
  • 13.6.1. Product Description
  • 13.6.2. Other Developmental Activities
  • 13.6.3. Clinical Development
  • 13.6.4. Safety and Efficacy
• 13.7. Dendritic Cell-based p53 Vaccine + Nivolumab + Ipilimumab: MultiVir
  • 13.7.1. Product Description
  • 13.7.2. Other Developmental Activities
  • 13.7.3. Clinical Development
  • 13.7.4. Safety and Efficacy

14. Small Cell Lung cancer Market: Seven Major Market Analyses

• 14.1. Key Findings
• 14.2. Small Cell Lung Cancer Market Outlook: 7MM
• 14.3. Total Market Size of Small-cell Lung Cancer in the 7MM
• 14.4. Conjoint Analysis of Small Cell Lung cancer Therapies
• 14.5. Key Small Cell Lung Cancer Market Forecast Assumptions
• 14.6. United States Small Cell Lung Cancer Market Size
  • 14.6.1. Total Market size of Small-cell Lung Cancer in the United States
  • 14.6.2. Market Size of Small-cell Lung Cancer by Therapeutic Class in the US
• 14.7. EU4 and the UK Small Cell Lung Cancer Market Size
  • 14.7.1. Total Market size of Small-cell Lung Cancer in EU4 and the UK
  • 14.7.2. Market Size of Small-cell Lung Cancer by Therapeutic Class in EU4 and the UK
• 14.8. Japan Small Cell Lung Cancer Market Size
  • 14.8.1. Total Market size of Small-cell Lung Cancer in Japan
  • 14.8.2. Market Size of Small-cell Lung Cancer by Therapeutic Class in Japan

15. Small Cell Lung Cancer Unmet Needs

16. Small Cell Lung Cancer SWOT Analysis

17. Small Cell Lung Cancer KOL Views

18. Small Cell Lung Cancer Market Access and Reimbursement Scenario

19. Appendix

• 19.1. Bibliography
• 19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight